CurrentBlue Cross Blue Shield - TexasPolicy CPCPLAB032

Oral Cancer Screening and Testing

Defines Blue Cross Blue Shield of Texas reimbursement criteria for laboratory testing related to oral cavity and oropharyngeal cancers, including HPV tumor status testing and exclusions for certain salivary biomarker and composite panel tests; applies to BCBSTX plans and providers submitting claims.

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyOral Cancer Screening and Testing

Policy CodePolicy CPCPLAB032

Change TypeRevisions and additions (reimbursable intent clarifiedexclusions addedcodes updated)

Effective DateMay 15, 2025

Next Review DateN/A

Key ActionSubmit accurate documentation and valid code combinations; claims are subject to plan documents, provider contracts, medical policies, and claim review.

SourceLink

POLICY UPDATE CHANGES

Revised intent of testing statement to specify: 'To establish HPV tumor status for individuals with oropharyngeal squamous cell carcinoma, testing for high-risk HPV testing with either MRNA expression testing for HPV E6/E7 or immunohistochemistry may be reimbursable.'

Added explicit non-reimbursable items: salivary biomarker testing (e.g., peptides/proteins, nucleic acids, metabolites) and panels that incorporate genetic risk factors with nongenetic biomarkers (e.g., mRNA CancerDetect™).

Added procedure codes 87626 and 0429U; removed procedure code 87623.

2reimbursement guidance items

9procedure codes listed

1policy version

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyOral Cancer Screening and Testing

Policy CodePolicy CPCPLAB032

Change TypeRevisions and additions (reimbursable intent clarifiedexclusions addedcodes updated)

Effective DateMay 15, 2025

Next Review DateN/A

Key ActionSubmit accurate documentation and valid code combinations; claims are subject to plan documents, provider contracts, medical policies, and claim review.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Reimbursement Criteria

Coverage criteria for oral cancer screening and testing

Coverage is conditional and delineates reimbursable use of HPV testing and explicit exclusions for other tests used to screen or diagnose oral cancer.

Reimbursable indication: To establish HPV tumor status for individuals with oropharyngeal squamous cell carcinoma, testing for high-risk HPV with either mRNA expression testing for HPV E6/E7 or immunohistochemistry may be reimbursable.

Exclusions (NOT reimbursable)

Salivary biomarker testing used to screen, detect, or diagnose oral cancer (for example, tests measuring peptides/proteins, nucleic acids, or metabolites).
Panels that incorporate genetic risk factors with nongenetic biomarkers for screening, detection, or diagnosis of oral cancer (for example, mRNA CancerDetect™).

Procedure codes listed in the policy (for example: 81599, 82397, 87624, 87625, 87626, 88341, 88342, 0296U, 0429U) are informational; inclusion does not guarantee coverage and claims remain subject to applicable plan documents, provider contracts, and claim review processes.

Procedure Codes and Coding Notes

Procedure codes referencedmixed

81599	Unlisted molecular pathology procedure
82397	Tumor marker assay
87624	HPV DNA or RNA detection (specific)
87625	HPV genotyping
87626	Added code (per policy list)
88341	Immunohistochemistry, per specimen; initial single antibody stain
88342	Immunohistochemistry, each additional single antibody stain
0296U	Molecular test (specific descriptor per code set)
0429U	Added code (per policy list)

Reimbursable indication threshold

Operational ruleHPV testing is reimbursable only to establish tumor HPV status in individuals with oropharyngeal squamous cell carcinoma when performed using high‑risk HPV mRNA E6/E7 expression testing or immunohistochemistry.

ScopeApplies only to testing intended to establish tumor HPV status for OPSCC (not for general screening or detection).

Accepted test typesHigh‑risk HPV mRNA E6/E7 expression testing; immunohistochemistry (IHC).

Reimbursement conditionCoverage is conditional and limited to the specified clinical indication and test methods; claims remain subject to plan documents and claim review.

Claims, Documentation, and Billing Guidance

Documentation Required

Claims documentation, coding, and review obligations

Providers must submit accurate documentation of services rendered and use valid code combinations from HIPAA-approved code sets when filing claims. Claims are subject to plan document terms, provider contract language, medical and coding policies, code edit protocols, and claim review; additional documentation may be requested upon claim review.

Submit claims using valid code combinations from HIPAA-approved code sets (e.g., CPT, HCPCS, ICD-10-CM/PCS).
Code claims according to industry-standard coding guidelines (Uniform Billing, AMA CPT resources, CMS NCCI policies and edits).
Be prepared to provide additional documentation upon request to support services billed.
Claims remain subject to the member’s plan document and any applicable provider contract; plan documents or contracts govern in the event of conflict.

Definitions and Test Type Clarifications

Testing to establish tumor HPV status (definition)

DefinitionTesting to establish tumor HPV status for oropharyngeal squamous cell carcinoma (OPSCC), e.g., high‑risk HPV testing via mRNA E6/E7 expression or immunohistochemistry.

Clinical intentDetermine tumor HPV status in individuals diagnosed with OPSCC to inform clinical management and staging.

Acceptable methodsmRNA expression testing targeting HPV E6/E7; immunohistochemistry (IHC) assays.

LimitationsNot intended for population screening, saliva‑based detection, or non‑tumor surveillance purposes.

Non‑reimbursable salivary biomarker testing and mixed panels

DefinitionSalivary biomarker testing refers to assays of peptides/proteins, nucleic acids, or metabolites from saliva for oral cancer-related purposes.